Recombinant Human SARS-CoV-2 Spike Protein RBD

新冠病毒RBD蛋白 | 重组人 SARS-CoV-2 刺突蛋白 RBD

SARS-CoV-2 RBD Protein | SARS-CoV-2 Spike RBD Protein | SARS-CoV-2 S Protein RBD

rp155929-1mg

1mg

无动物源

≥95%(SDS-PAGE)

＞95% (SDS-PAGE)

Purity:>95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： The spike (S) glycoprotein of coronaviruses contains protrusions that will only bind to certain receptors on the host cell. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase-4; APN, aminopeptidase N; CEACAM, carcinoembryonic antigen-related cell adhesion molecule 1; Sia, sialic acid; O-ac Sia, O-acetylated sialic acid. The spike is essential for both host specificity and viral infectivity. The term 'peplomer' is typically used to refer to a grouping of heterologous proteins on the virus surface that function together. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. It's been reported that SARS-CoV-2 (COVID-19 coronavirus, 2019-nCoV) can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion. The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. The main functions for the Spike protein are summarized as: Mediate receptor binding and membrane fusion; Defines the range of the hosts and specificity of the virus; Main component to bind with the neutralizing antibody; Key target for vaccine design; Can be transmitted between different hosts through gene recombination or mutation of the receptor binding domain (RBD), leading to a higher mortality rate.

1. Immobilized Recombinant Human SARS-CoV-2 Spike Protein RBD (rp155929) at 5.0 μg/mL can bind Recombinant Human ACE-2 Protein (rp176242) with the EC50 of 75.79 ng/mL. 2. Immobilized Recombinant Human SARS-CoV-2 Spike Protein RBD (rp155929) at 1.0 μg/mL can bind Regdanvimab (anti-Spike RBD) (Ab182925) with the EC50 of 12.65 ng/mL. 3. Immobilized Recombinant Human SARS-CoV-2 Spike Protein RBD (rp155929) at 1.0 μg/mL can bind Imdevimab (anti-Spike RBD) (Ab182897) with the EC50 of 7.82 ng/mL. 4. Immobilized Recombinant Human SARS-CoV-2 Spike Protein RBD (rp155929) at 1.0 μg/mL can bind Etesevimab (anti-Spike RBD) (Ab182932) with the EC50 of 23.96 ng/mL. 5. Immobilized Recombinant Human SARS-CoV-2 Spike Protein RBD (rp155929) at 1.0 μg/mL can bind Sotrovimab (anti-Spike RBD) (Ab182938) with the EC50 of 41.33 ng/mL. 6. Immobilized Recombinant Human SARS-CoV-2 Spike Protein RBD (rp155929) at 1.0 μg/mL can bind Casirivimab (anti-Spike RBD) (Ab182896) with the EC50 of 10.50 ng/mL.

重组表达

26.9 kDa

C-His

36.4 kDa, reducing conditions; 34.2 kDa, non-reducing conditions

HEK293 Accession #: P0DTC2 | HEK293

<1.0 EU/μg

严重急性呼吸系统综合征冠状病毒2型(SARS-CoV-2)

319-541 aa

MRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFENLYFQGHHHHHH

Yes

Yes